Related Experiment Video
Updated: May 7, 2026
10:09
A Straightforward Method for Glucosinolate Extraction and Analysis with High-pressure Liquid Chromatography (HPLC)
Published on: March 15, 2017
Lignan glucosides from Sinomenium acutum rhizomes
Ki Hyun Kim1, Sae Rom Moon, Chung Sub Kim
1Natural Products Laboratory, School of Pharmacy, Sungkyunkwan University.
Bioscience, Biotechnology, and Biochemistry
|October 8, 2013
Summary
A new lignan glucoside, acutumoside, was isolated from Sinomenium acutum. Some compounds showed antiproliferative activity against human tumor cells, though acutumoside itself had weak effects.
Area of Science:
- Phytochemistry
- Natural Products Chemistry
- Pharmacology
Background:
- Sinomenium acutum is a traditional medicinal plant.
- Isolation and structural elucidation of compounds from medicinal plants are crucial for discovering new therapeutic agents.
Purpose of the Study:
- To isolate and characterize new and known compounds from Sinomenium acutum rhizomes.
- To evaluate the antiproliferative activity of the isolated compounds against human tumor cell lines.
Main Methods:
- Isolation of compounds using chromatographic techniques.
- Structure elucidation using extensive spectroscopic analyses, including 2D-NMR.
- Antiproliferative activity assay against A549, SK-OV-3, SK-MEL-2, and HCT-15 cell lines.
Main Results:
- A new lignan glucoside, acutumoside (1), was isolated along with nine known compounds.
- Compounds 2, 7, 8, and 10 exhibited potential antiproliferative activity.
- Acutumoside (1) displayed weak antiproliferative activity against the tested human tumor cell lines.
Conclusions:
- Sinomenium acutum is a source of bioactive lignan glucosides.
- Compounds 2, 7, 8, and 10 warrant further investigation for their anticancer potential.
- Acutumoside, while structurally novel, shows limited antiproliferative effects in this study.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...